Branched Polylactide Derivatives for Stable Drug Micelles
Solution Overview
Problem
Existing drug delivery systems using polylactic acid derivatives are limited by the inability to form stable micelles in aqueous solutions at higher molecular weights, restricting their ability to solubilize and sustain poorly water-soluble drugs due to an imbalance between hydrophilic and hydrophobic groups, and the non-degradability of hydrophilic polymers like polyethylene glycol.
Innovation Solution
Development of branched polylactic acid derivatives with carboxy groups or carboxy alkali metal salt groups at each terminal, allowing for increased molecular weight and stability of micelles, enabling solubilization of poorly water-soluble drugs by balancing hydrophilic and hydrophobic components and ensuring biodegradability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If linear polylactic acid derivatives with carboxyl groups are used to form micelles, then micelle formation is achieved at low molecular weight (2,000 Dalton or less), but micelle stability is poor and drug entrapment is insufficient
Solution Approach 1:
The patent divides the polylactic acid structure into multiple branches radiating from a central core, creating a star-shaped architecture. This segmentation allows each branch to contribute to micelle stability while the overall structure provides enhanced drug entrapment capacity, resolving the contradiction between stability and productivity.
Solution Approach 2:
The invention creates a composite structure combining hydrophobic polylactic acid chains with hydrophilic carboxyl terminal groups. This composite architecture enables the formation of stable micelles with improved drug entrapment, as the hydrophobic core stabilizes the micelle while the hydrophilic exterior enhances solubility and drug loading.
2Reliability
If hydrophilic polymer such as polyethylene glycol is added to create core-shell structure, then micelle formation and drug solubilization are improved, but biodegradability is reduced because polyethylene glycol is not completely degraded
Solution Approach 1:
The patent removes the non-biodegradable polyethylene glycol component from the core-shell structure and replaces it entirely with biodegradable polylactic acid chains terminated with carboxyl groups. This extraction eliminates the harmful non-biodegradable element while maintaining the micelle formation and drug solubilization capabilities through the modified polylactic acid architecture.
3Object-generated harmful factors
If only biodegradable polyester like polylactic acid is used without hydrophilic polymer, then biodegradability is maintained, but micelle formation capability is lost due to hydrophobicity
Solution Approach 1:
The patent applies local quality modification by introducing carboxyl terminal groups at the ends of polylactic acid chains. These localized hydrophilic carboxyl groups at the chain ends provide the necessary amphiphilic character for micelle formation, while the bulk of the polymer remains hydrophobic and biodegradable, thus maintaining both micelle formation capability and biodegradability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The branched polylactic acid derivatives form stable micelles in aqueous solutions of pH 4 or more, effectively solubilizing poorly water-soluble drugs, enhancing their bioavailability and pharmacological effects while maintaining stability and biocompatibility.
Implementation Method 1
the branched polylactic acid derivative can form micelles in aqueous solution
Implementation Method 2
effectively solubilizing poorly water-soluble drugs
Implementation Method 3
balance between hydrophilic group and hydrophobic group is adjusted by binding carboxyl group to the terminal
Data Source
AI summary
The present invention relates to a biodegradable branched polylactic acid derivative of formula 1, and preparation method and use thereof: <formula 1> 1-(R—X)n wherein each of X, R, I and n is defined as in the detailed description.



